In concordance with the genetic knockout data (Fig. 4A–D), FLT3(ITD)-positive AML 201 and AML1 patient cells (Fig. 4E, F) and JAK2(V617F)-positive MPN1 and P293 MPN patient cells (Fig. 4G, H) were more sensitive to the combination of ALDHi and Polθi when compared to treatment with these drugs used as single agents. This evidence concerns the gene FLT3 and acute myeloid leukemia.